Stylus Medicine develops transformative in vivo genetic medicines by combining sequence-specific, therapeutic-grade recombinases with cell-targeted lipid nanoparticle (LNP) delivery. Its platform is designed to encode polyfunctional multi-kilobase payloads with high efficiency, specificity, and fidelity, enabling durable and scalable in vivo cell engineering. The approach aims to overcome limitations of ex vivo and viral manufacturing and to simplify patient treatment workflows. Stylus intends to start by enabling in vivo CAR-T therapies and positions its technology for applications across oncology, autoimmune, and genetic diseases. The company emerged from stealth with $85 million in financing and will use the proceeds to advance its platform and pipeline of in vivo therapeutic programs. Stylus is led by industry veterans including Chairman and CEO Emile Nuwaysir and CSO Jason Fontenot and is based in Cambridge, Massachusetts; it was created in 2022 by Raven, RA Capital’s incubator, and Khosla Ventures.

Total raised

$45M

Funding rounds

1

Latest round

Series A

Latest activity

May 2025